Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01349361

Enrollment

Unknown

Registered

2011-05-06

Start date

2011-03-31

Completion date

Unknown

Last updated

2011-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinomas, Photodynamic Therapy

Brief summary

Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.

Interventions

PROCEDUREDaylight mediated photodynamic therapy

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* superficial BCC

Exclusion criteria

* Immunosuppression

Design outcomes

Primary

Measure	Time frame
complete disappearance of the BCC	—

Countries

Denmark

Contacts

Primary ContactStine R Wiegell, MD, PhD

swie0001@bbh.regionh.dk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026